Drug delivery by oral inhalation - Simplified

Andrea Leone-Bay
MannKind Corporation, USA

Drug delivery by oral inhalation has been the accepted standard for the treatment of pulmonary disease for decades. Recently however, the development of a simple, cost-effective oral inhalation system has opened this route of administration to a wide variety of non-pulmonary indications including diabetes, pain, and osteoporosis. This new delivery system comprises dry powder formulations and patient-friendly devices that allow patients to self-administer medicines using simple, breath-powered inhalers. This approach can be used with new therapies to gain competitive advantage or to breathe new life into “old” drugs to expand patent protection and manage product life cycles.

Biography

Andrea Leone-Bay holds a Ph.D. in Organic Chemistry and has worked in the pharmaceutical industry for over 25 years. She has published 47 manuscripts in peer-reviewed journals and is an inventor of 87 issued U.S. patents. Her primary areas of expertise include chemistry and formulations research and development for oral and inhaled drug delivery. In particular, she is interested in the development of formulation/device combination products for the oral inhalation delivery of peptides, proteins and small molecule drugs for diabetes, osteoporosis, asthma and COPD. She is currently Vice President of Pharmaceutical Research & Development at MannKind Corporation.

aleone-bay@mannkindcorp.com